PP
GMAB icon

PDS Planning’s Genmab GMAB Stock Holding History

PDS Planning’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$200K Sell
7,293
-171
-2% -$4.54K 0.01% 579
2026
Q1 		$200K Sell
7,464
-795
-10% -$23.8K 0.01% 526
2025
Q4 		$254K Buy
8,259
+212
+3% +$6.61K 0.02% 429
2025
Q3 		$247K Buy
+8,047
New +$196K 0.02% 433

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

PDS Planning's GMAB Position: Q2 2026 in Review

PDS Planning reduced its Genmab (GMAB) stake by 2.3% in Q2 2026, selling an estimated $4.54K and leaving 7,293 shares worth $200K. The position accounts for 0.01% of the portfolio, ranked #579.

PDS Planning first reported a position in GMAB in Q3 2025 and has held it in 4 quarters since. The position peaked at $254K in Q4 2025. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • PDS Planning held 7,293 shares of Genmab worth $200K as of Q2 2026.
  • PDS Planning sold 171 Genmab shares in Q2 2026, an estimated $4.54K.
  • Genmab made up 0.01% of PDS Planning's portfolio in Q2 2026, its #579 holding.
  • PDS Planning first reported a position in Genmab in Q3 2025 and has held it in 4 quarters since.
  • PDS Planning's Genmab position peaked at $254K in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on PDS Planning's 13F filing for Q2 2026, filed 5 Aug 2026.